Martek, Numico deal
This article was originally published in The Tan Sheet
Executive Summary
Nutritional oil manufacturer Martek Biosciences will exclusively supply infant formula producer Numico with ARA and microbially-derived DHA for its infant formula products under a 15-year deal between the firms, Martek announces Feb. 19. The agreement extends an existing license agreement that has been in place since 1994, but allows Numico to terminate the arrangement as early as January 2012, Martek states. "With this new agreement, more than 70 percent of Martek's business in the infant formula market is subject to multi-year sole source agreements," firm notes...
You may also be interested in...
Martek Revenues Grow On International Demand For life’sDHA
Sales of life'sDHA to international infant formula manufacturers helped drive nutritional oil developer Martek Biosciences' revenue up 18 percent to a record $82.9 million during its fiscal 2008 first quarter, the firm says
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
BMS Has A Strong Pipeline, But Access Challenges Remain
Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.